

# MATERIAL SAFETY DATA SHEET

Version No: MSDS/Irino-AUS/DP-004

Effective Date: 11<sup>th</sup> March 2020

IRINOTECAN HYDROCHLORIDE CONCENTRATED INJECTION  
40 MG/2 ML, 100 MG/5 ML, 300 MG/15 ML and 500 MG/25 ML

## SECTION 1 – PRODUCT AND COMPANY IDENTIFICATION

**Product Name:** Irinotecan Hydrochloride Concentrated Injection 40 mg/2 mL, 100 mg/5 mL, 300 mg/15 mL and 500 mg/5 mL

| Sponsor   | Manufacturer  |
|---|---|
| Accord Healthcare Pty Ltd<br>Level 24, 570 Bourke Street,<br>Melbourne, VIC, 3000,<br>Australia | Intas Pharmaceuticals Ltd.<br>Plot No. 457, 458<br>Village-Matoda,<br>Bavla Road, Ta. Sanand,<br>Dist. Ahmedabad-382 210,<br>Gujarat, India |

## SECTION 2 – COMPOSITION, INFORMATION ON INGREDIENTS

**Active:** Irinotecan Hydrochloride.

**Inactive:** Sorbitol, Lactic acid, Water for Injections, Sodium hydroxide and Hydrochloric acid.

| Ingredient               | CAS Number  | EU EINECS/ELINCS List | GHS Classification  | %  |
|--------------------------|-------------|-----------------------|---|----|
| Irinotecan Hydrochloride | 100286-90-6 | Not Listed            | Acute Tox.4 (H302)<br>Repr.1B (H360D)<br>Muta.2 (H341)                        | 2% |
| Sodium hydroxide         | 1310-73-2   | 215-185-5             | Skin Corr.1A (H314)   | ** |
| Lactic acid              | 50-21-5     | 200-018-0             | Eye Dam. 1 (H318)<br>Skin Irrit. 2 (H315)                                     | *  |
| Hydrochloric acid        | 7647-01-0   | 231-595-7             | STOT SE 3 (H335)<br>Skin Corr. 1A (H314)<br>Press. Gas<br>Acute Tox. 3 (H331) | ** |
| Sorbitol                 | 50-70-4     | 200-061-5             | Not Listed  | *  |
| Water for Injections     | 7732-18-5   | 231-791-2             | Not Listed  | *  |

**Additional Information:** \* Proprietary \*\* to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

# MATERIAL SAFETY DATA SHEET

Version No: MSDS/Irino-AUS/DP-004

Effective Date: 11<sup>th</sup> March 2020

## SECTION 3 - HAZARDS IDENTIFICATION

### Classification of the Substance or Mixture:

#### GHS – Classification:

Germ Cell Mutagenicity : Category 2  
Reproductive Toxicity : Category 1B

#### Label Elements:

**Signal Word:** Danger

#### Hazard Statements:

H341 - Suspected of causing genetic defects  
H360D - May damage the unborn child

#### Precautionary Statements:

P202 - Do not handle until all safety precautions have been read and understood  
P281 - Use personal protective equipment as required  
P308 + P313 - IF exposed or concerned: Get medical attention/advice  
P405 - Store locked up  
P501 - Dispose of contents/container in accordance with all local and national regulations



**Other Hazards:** An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

**Note:** This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## SECTION 4 - EMERGENCY & FIRST AID MEASURES

### Description of First Aid Measures:

# MATERIAL SAFETY DATA SHEET

**Version No:** MSDS/Irino-AUS/DP-004

**Effective Date:** 11<sup>th</sup> March 2020

**Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

## **Most Important Symptoms and Effects, Both Acute and Delayed:**

**Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 3 – Hazards Identification and/or Section 11 - Toxicological Information.

**Medical Conditions Aggravated by Exposure:** None known

**Indication of the Immediate Medical Attention and Special Treatment Needed:**

**Notes to Physician:** None

## **SECTION 5 - FIRE FIGHTING MEASURES**

**Extinguishing Media:** Extinguish fires with CO<sub>2</sub>, extinguishing powder, foam, or water.

**Special Hazards Arising from the Substance or Mixture:**

**Hazardous Combustion Products:** Formation of toxic gases is possible during heating or fire.

**Fire / Explosion Hazards:** Not flammable.

**Advice for Fire-Fighters:** During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

## **SECTION 6 - ACCIDENTAL RELEASE MEASURES**

**Personal Precautions, Protective Equipment and Emergency Procedures:** Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

# MATERIAL SAFETY DATA SHEET

**Version No:** MSDS/Irino-AUS/DP-004

**Effective Date:** 11<sup>th</sup> March 2020

---

**Environmental Precautions:** Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

## **Methods and Material for Containment and Cleaning Up:**

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

## **SECTION 7 - HANDLING AND STORAGE**

**Precautions for Safe Handling:** Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

## **Conditions for Safe Storage, Including any Incompatibilities:**

**Storage Conditions:** Store as directed by product packaging.

**Specific end use(s):** Pharmaceutical product used as Antineoplastic

## **SECTION 8 - EXPOSURE CONTROLS/PERSONAL PROTECTION**

### **Control Parameters:**

**Refer to available public information for specific member state Occupational Exposure Limits.**

### **Irinotecan Hydrochloride:**

**OEL TWA-8 Hr** : 2 µg/m<sup>3</sup>

### **Sodium hydroxide:**

**ACGIH Ceiling Threshold Limit** : 2 mg/m<sup>3</sup>

**Australia PEAK** : 2 mg/m<sup>3</sup>

**Austria OEL – MAKs** : 2 mg/m<sup>3</sup>

# MATERIAL SAFETY DATA SHEET

Version No: MSDS/Irino-AUS/DP-004

Effective Date: 11<sup>th</sup> March 2020

---

|                                 |                         |
|---------------------------------|-------------------------|
| <b>Bulgaria OEL – TWA</b>       | : 2.0 mg/m <sup>3</sup> |
| <b>Czech Republic OEL – TWA</b> | : 1 mg/m <sup>3</sup>   |
| <b>Estonia OEL – TWA</b>        | : 1 mg/m <sup>3</sup>   |
| <b>France OEL – TWA</b>         | : 2 mg/m <sup>3</sup>   |
| <b>Greece OEL – TWA</b>         | : 2 mg/m <sup>3</sup>   |
| <b>Hungary OEL – TWA</b>        | : 2 mg/m <sup>3</sup>   |
| <b>Japan - OELs – Ceilings</b>  | : 2 mg/m <sup>3</sup>   |
| <b>Latvia OEL – TWA</b>         | : 0.5 mg/m <sup>3</sup> |
| <b>OSHA - Final PELs - TWAs</b> | : 2 mg/m <sup>3</sup>   |
| <b>Poland OEL – TWA</b>         | : 0.5 mg/m <sup>3</sup> |
| <b>Slovakia OEL – TWA</b>       | : 2 mg/m <sup>3</sup>   |
| <b>Slovenia OEL – TWA</b>       | : 2 mg/m <sup>3</sup>   |
| <b>Sweden OEL – TWAs</b>        | : 1 mg/m <sup>3</sup>   |
| <b>Switzerland OEL -TWAs</b>    | : 2 mg/m <sup>3</sup>   |

## Hydrochloric acid:

|                                      |                                  |
|--------------------------------------|----------------------------------|
| <b>ACGIH Ceiling Threshold Limit</b> | : 2 ppm                          |
| <b>Australia PEAK</b>                | : 5 ppm<br>7.5 mg/m <sup>3</sup> |
| <b>Austria OEL - MAKs</b>            | : 5 ppm<br>8 mg/m <sup>3</sup>   |
| <b>Belgium OEL - TWA</b>             | : 5 ppm<br>8 mg/m <sup>3</sup>   |
| <b>Bulgaria OEL - TWA</b>            | : 5 ppm<br>8.0 mg/m <sup>3</sup> |
| <b>Cyprus OEL - TWA</b>              | : 5 ppm<br>8 mg/m <sup>3</sup>   |
| <b>Czech Republic OEL - TWA</b>      | : 8 mg/m <sup>3</sup>            |
| <b>Estonia OEL - TWA</b>             | : 5 ppm<br>8 mg/m <sup>3</sup>   |
| <b>Germany - TRGS 900 - TWAs</b>     | : 2 ppm<br>3 mg/m <sup>3</sup>   |
| <b>Germany (DFG) - MAK</b>           | : 2 ppm<br>3.0 mg/m <sup>3</sup> |
| <b>Greece OEL - TWA</b>              | : 5 ppm<br>7 mg/m <sup>3</sup>   |
| <b>Hungary OEL - TWA</b>             | : 8 mg/m <sup>3</sup>            |
| <b>Ireland OEL - TWAs</b>            | : 5 ppm<br>8 mg/m <sup>3</sup>   |
| <b>Italy OEL - TWA</b>               | : 5 ppm<br>8 mg/m <sup>3</sup>   |
| <b>Japan - OELs - Ceilings</b>       | : 2 ppm<br>3.0 mg/m <sup>3</sup> |
| <b>Latvia OEL - TWA</b>              | : 5 ppm<br>8 mg/m <sup>3</sup>   |
| <b>Lithuania OEL - TWA</b>           | : 5 ppm<br>8 mg/m <sup>3</sup>   |

# MATERIAL SAFETY DATA SHEET

Version No: MSDS/Irino-AUS/DP-004

Effective Date: 11<sup>th</sup> March 2020

---

|                              |                                  |
|------------------------------|----------------------------------|
| <b>Luxembourg OEL - TWA</b>  | : 5 ppm<br>8 mg/m <sup>3</sup>   |
| <b>Malta OEL - TWA</b>       | : 5 ppm<br>8 mg/m <sup>3</sup>   |
| <b>Netherlands OEL - TWA</b> | : 8 mg/m <sup>3</sup>            |
| <b>Poland OEL - TWA</b>      | : 5 mg/m <sup>3</sup>            |
| <b>Portugal OEL - TWA</b>    | : 5 ppm<br>8 mg/m <sup>3</sup>   |
| <b>Romania OEL - TWA</b>     | : 5 ppm<br>8 mg/m <sup>3</sup>   |
| <b>Slovakia OEL - TWA</b>    | : 5 ppm<br>8.0 mg/m <sup>3</sup> |
| <b>Slovenia OEL - TWA</b>    | : 5 ppm<br>8 mg/m <sup>3</sup>   |
| <b>Spain OEL - TWA</b>       | : 5 ppm<br>7.6 mg/m <sup>3</sup> |
| <b>Switzerland OEL -TWAs</b> | : 2 ppm<br>3.0 mg/m <sup>3</sup> |
| <b>Vietnam OEL - TWAs</b>    | : 5 mg/m <sup>3</sup>            |

**Analytical Method:** Analytical method available for Irinotecan hydrochloride.

## Exposure Controls:

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

**Personal Protective Equipment:** Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

**Hands:** Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

**Eyes:** Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

**Skin:** Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

# MATERIAL SAFETY DATA SHEET

Version No: MSDS/Irino-AUS/DP-004

Effective Date: 11<sup>th</sup> March 2020

**Respiratory protection:** Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)

## SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES

**Physical State** : Aqueous solution  
**Color** : Pale yellow  
**Odor** : No data available.  
**Odor Threshold** : No data available.  
**Molecular Formula** : Mixture  
**Molecular Weight** : Mixture  
**Solvent Solubility** : No data available  
**Water Solubility** : No data available  
**Solubility** : Soluble: Water  
**pH** : 3.5  
**Melting/Freezing Point (°C)** : No data available  
**Boiling Point (°C)** : No data available.

### Partition Coefficient:

#### Irinotecan Hydrochloride:

| Method   | pH  | Endpoint | Value |
|----------|-----|----------|-------|
| Measured | N/A | Log P    | 4.37  |

**Lactic acid** : No data available  
**Water for Injection** : No data available  
**Sodium hydroxide** : No data available  
**Hydrochloric acid** : No data available  
**Sorbitol** : No data available  
**Decomposition Temperature (°C)** : No data available  
**Evaporation Rate (Gram/s)** : No data available  
**Vapor Pressure (kPa)** : No data available  
**Vapor Density (g/ml)** : No data available  
**Relative Density** : No data available  
**Viscosity** : No data available

### Flammability:

**Autoignition Temperature (Solid) (°C)** : No data available  
**Flammability (Solids)** : No data available  
**Flash Point (Liquid) (°C)** : No data available  
**Upper Explosive Limits (Liquid) (% by Vol.)** : No data available  
**Lower Explosive Limits (Liquid) (% by Vol.)** : No data available

# MATERIAL SAFETY DATA SHEET

Version No: MSDS/Irino-AUS/DP-004

Effective Date: 11<sup>th</sup> March 2020

## SECTION 10 - STABILITY AND REACTIVITY

**Reactivity:** No data available

**Chemical Stability:** Stable under normal conditions of use.

**Possibility of Hazardous Reactions:**

**Oxidizing Properties:** No data available

**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions.

**Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

**Hazardous Decomposition Products:** No data available

## SECTION 11 - TOXICOLOGY INFORMATION

**General Information:** The information included in this section describes the potential hazards of the individual ingredients.

**Short Term:** May be harmful if swallowed. (based on components).

**Long Term:** Repeat-dose studies in animals have shown a potential to cause adverse effects on gastrointestinal system. Animal studies have shown a potential to cause adverse effects on the fetus.

**Known Clinical Effects:** Effects reported during clinical use included vomiting and diarrhea. Effects on blood and blood-forming organs have also occurred. Serious allergic reactions, including anaphylaxis, have been reported.

**Acute Toxicity:**

**Irinotecan Hydrochloride:**

| Species | Route | End Point | Dose      |
|---------|-------|-----------|-----------|
| Rat     | Oral  | LD 50     | 867 mg/kg |
| Rat     | Oral  | LD 50     | 1026mg/kg |

**Lactic acid:**

| Species | Route  | End Point | Dose         |
|---------|--------|-----------|--------------|
| Rat     | Oral   | LD50      | 3543 mg/kg   |
| Rabbit  | Dermal | LD50      | > 2000 mg/kg |



# MATERIAL SAFETY DATA SHEET

Version No: MSDS/Irino-AUS/DP-004

Effective Date: 11<sup>th</sup> March 2020

## Sodium hydroxide:

| Species | Route | End Point | Dose     |
|---------|-------|-----------|----------|
| Mouse   | IP    | LD50      | 40 mg/kg |

## Hydrochloric acid:

| Species | Route                     | End Point | Dose      |
|---------|---------------------------|-----------|-----------|
| Rat     | Sub-tenon injection (eye) | LC50 1H   | 3,124 ppm |
| Mouse   | Inhalation                | LC50 1H   | 1,108ppm  |
| Mouse   | Oral                      | LD50      | 900mg/kg  |

## Sorbitol:

| Species | Route           | End Point | Dose         |
|---------|-----------------|-----------|--------------|
| Mouse   | Oral            | LD50      | 17,800 mg/kg |
| Rat     | Para-periosteal | LD50      | 7100mg/kg    |

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

## Irritation / Sensitization:

### Irinotecan Hydrochloride:

| Study Type                                  | Species | Severity  |
|---|---------|-----------|
| Eye Irritation                              | Rabbit  | Minimal   |
| Skin Irritation                             | Rabbit  | No effect |
| Antigenicity- Passive cutaneous anaphylaxis | Mouse   | Negative  |

## Lactic acid:

| Study Type      | Species | Severity        |
|-----------------|---------|-----------------|
| Eye Irritation  | Rabbit  | Severe          |
| Skin Irritation | Rabbit  | Moderate Severe |

## Sodium hydroxide

| Study Type      | Species | Severity |
|-----------------|---------|----------|
| Eye Irritation  | Rabbit  | Severe   |
| Skin Irritation | Rabbit  | Severe   |

## Repeated Dose Toxicity:

### Irinotecan Hydrochloride

| Duration   | Species | Route       | Dose            | End Point | Target Organ                                 |
|------------|---------|-------------|-----------------|-----------|--|
| 4 Week(s)  | Rat     | Oral        | 10 mg/kg/day    | LOAEL     | Bone marrow, Gastrointestinal System         |
| 6 Month(s) | Rat     | Intravenous | 0.016 mg/kg/day | NOAEL     | Blood, Bone Marrow, Male reproductive system |
| 4 Week(s)  | Dog     | Oral        | 1 mg/kg/day     | NOAEL     | Bone Marrow, Gastrointestinal system         |
| 26 Week(s) | Dog     | Intravenous | 0.01 mg/kg/day  | NOAEL     | Blood  |

# MATERIAL SAFETY DATA SHEET

Version No: MSDS/Irino-AUS/DP-004

Effective Date: 11<sup>th</sup> March 2020

## Reproduction & Developmental Toxicity:

### Irinotecan Hydrochloride:

| Study Type                       | Species | Route       | Dose           | End Point | Effect(s)         |
|----------------------------------|---------|-------------|----------------|-----------|-------------------|
| Embryo / Fetal Development       | Rat     | Intravenous | 6 mg/kg/day    | NOAEL     | Fetotoxicity      |
| Embryo / Fetal Development       | Rabbit  | Intravenous | 6 mg/kg/day    | NOAEL     | Fetotoxicity      |
| Prenatal & Postnatal Development | Rat     | Intravenous | 6 mg/kg/day    | LOAEL     | Neonatal toxicity |
| Embryo / Fetal Development       | Rat     | Intravenous | 0.24 mg/kg/day | NOAEL     | Teratogenic       |
| Embryo / Fetal Development       | Rabbit  | Intravenous | 0.06 mg/kg/day | NOAEL     | Teratogenic       |

### Lactic acid

| Study Type               | Species | Route | Dose           | End Point | Effect(s)                  |
|--------------------------|---------|-------|----------------|-----------|----------------------------|
| Reproductive & Fertility | Rat     | Oral  | 6.25 mg/kg/day | NOEL      | Fertility, Not teratogenic |

## Genetic Toxicity:

### Irinotecan Hydrochloride:

| Study Type                    | Cell Type/Organism                | Result   |
|-------------------------------|-----------------------------------|----------|
| Bacterial Mutagenicity (Ames) | <i>Salmonella</i>                 | Negative |
| <i>In Vitro</i> Cytogenetics  | Chinese Hamster Ovary (CHO) cells | Positive |
| <i>In Vivo</i> Micronucleus   | Mouse                             | Positive |

## Carcinogenicity:

### Irinotecan Hydrochloride:

| Duration    | Species | Route       | Dose         | End Point | Effect(s)        |
|-------------|---------|-------------|--------------|-----------|------------------|
| 104 Week(s) | Rat     | Intravenous | 2 mg/kg/week | NOAEL     | Not carcinogenic |

**Carcinogen Status:** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

### Hydrochloric acid:

**IARC:** Group 3 (Not Classifiable)

## SECTION 12 - ENVIRONMENTAL IMPACT INFORMATION

**Environmental Overview:** The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

**Toxicity:** No data available

**Persistence and Degradability:** No data available

# MATERIAL SAFETY DATA SHEET

Version No: MSDS/Irino-AUS/DP-004

Effective Date: 11<sup>th</sup> March 2020

## Bio-accumulative Potential:

### Partition Coefficient:

#### Irinotecan Hydrochloride:

| Method   | pH  | Endpoint | Value |
|----------|-----|----------|-------|
| Measured | N/A | Log P    | 4.3   |

**Mobility in Soil:** No data available

## SECTION 13 - DISPOSAL INFORMATION

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

## SECTION 14 - TRANSPORTATION INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

## SECTION 15 - REGULATORY INFORMATION

### Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

#### Irinotecan Hydrochloride:

**CERCLA/SARA 313 Emission reporting** : Not Listed  
**California Proposition 65** : Not Listed  
**EU EINECS/ELINCS List** : Not Listed

#### Sorbitol:

**CERCLA/SARA 313 Emission reporting** : Not Listed  
**California Proposition 65** : Not Listed

# MATERIAL SAFETY DATA SHEET

Version No: MSDS/Irino-AUS/DP-004

Effective Date: 11<sup>th</sup> March 2020

---

**Inventory - United States TSCA - Sect. 8(b)** : Present  
**Australia (AICS)** : Present  
**REACH - Annex IV - Exemptions from the obligations of Register** : Present  
**EU EINECS/ELINCS List** : 200-061-5

## Sodium hydroxide:

**CERCLA/SARA 313 Emission reporting** : Not Listed  
**CERCLA/SARA Hazardous Substances and their Reportable Quantities** : 1000 lb  
454 kg  
**California Proposition 65** : Not Listed  
**Inventory - United States TSCA - Sect. 8(b)** : Present  
**Australia (AICS)** : Present  
**Standard for the Uniform Scheduling for Drugs and Poisons** : Schedule 5  
Schedule 6  
**EU EINECS/ELINCS List** : 215-185-5

## Lactic acid:

**CERCLA/SARA 313 Emission reporting** : Not Listed  
**California Proposition 65** : Not Listed  
**Inventory - United States TSCA - Sect. 8(b)** : Present  
**Australia (AICS):** : Present  
**EU EINECS/ELINCS List** : 200-018-0

## Water for Injection:

**CERCLA/SARA 313 Emission reporting** : Not Listed  
**California Proposition 65** : Not Listed  
**Inventory - United States TSCA - Sect. 8(b)** : Present  
**Australia (AICS)** : Present  
**REACH - Annex IV - Exemptions from the obligations of Register** : Present  
**EU EINECS/ELINCS List** : 231-791-2

## Hydrochloric acid:

**CERCLA/SARA 313 Emission reporting** : 1.0 %  
**CERCLA/SARA Hazardous Substances and their Reportable Quantities:** : 5000 lb  
2270 kg  
**CERCLA/SARA - Section 302 Extremely Hazardous TPQs** : 500 lb  
**CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs** : 5000 lb  
**California Proposition 65** : Not Listed  
**Inventory - United States TSCA - Sect. 8(b)** : Present  
**Australia (AICS)** : Present  
**Standard for the Uniform Scheduling for Drugs and Poisons** : Schedule 5  
Schedule 6  
**EU EINECS/ELINCS List** : 231-595-7

# MATERIAL SAFETY DATA SHEET

**Version No:** MSDS/Irino-AUS/DP-004

**Effective Date:** 11<sup>th</sup> March 2020

## SECTION 16 - OTHER DATA

### **Text of CLP/GHS Classification abbreviations mentioned in Section 3**

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed

Acute toxicity, inhalation-Cat.3; H331 - Toxic if inhaled

Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage

Serious eye damage/eye irritation-Cat.1; H318 - Causes serious eye damage

Skin corrosion/irritation-Cat.2; H315 - Causes skin irritation

Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation

**Data Sources:** Information from published literature.

The information in this document is believed to be correct as of the date issued. HOWEVER, NO WARRANTY OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR ANY OTHER WARRANTY IS EXPRESSED OR IS TO BE IMPLIED REGARDING THE ACCURACY OR COMPLETENESS OF THIS INFORMATION, THE RESULTS TO BE OBTAINED FROM THE USE OF THIS INFORMATION OR THE PRODUCT, THE SAFETY OF THIS PRODUCT, OR THE HAZARDS RELATED TO ITS USE. This information and product are furnished on the condition that the person receiving them shall make his own determination as to the suitability of the product for his particular purpose and on the condition that he assume the risk of his use thereof.